Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: Results from the randomized phase II CLIO trial-MedSci.cn

Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: Results from the randomized phase II CLIO trial

Vanderstichele, A; Loverix, L; De Vogelaere, C; Heyrman, L; Van Gorp, T; Van Nieuwenhuysen, E; Han, S; Olbrecht, SJAR; Berteloot, P; Neven, P; Schepers, R; Busschaert, P; Goossens, D; Lambrechts, D; Vergote, IB

ANNALS OF ONCOLOGY, 2020; 31 (): S617

科室
- - 订阅+
  - 更多科室
工具
服务

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: Results from the randomized phase II CLIO trial

科室

工具

服务